1. Background {#sec1-jcm-09-00783}
=============

In 2015, an estimated 1.7 million Australian adults aged 18 years or older had indicators of chronic kidney disease (CKD), and of these, 604,000 had CKD stages 3--5 \[[@B1-jcm-09-00783]\]. Diabetes and hypertension caused up to two-thirds of CKD cases. Approximately one in three and three in four Australian general practice patients with CKD had recorded diagnoses of diabetes and hypertension, respectively \[[@B2-jcm-09-00783]\]. Progressive kidney damage with hypertension and diabetes leads to end-stage kidney disease (ESKD) \[[@B3-jcm-09-00783]\]. In 2016 alone, 2800 new cases of ESKD were reported in Australia \[[@B4-jcm-09-00783]\]. Patients with ESKD require expensive replacement therapy, and their treatment costs the Australian economy 1 billion per year \[[@B1-jcm-09-00783]\].

Prevention of CKD progression is cost-effective and is most successful within primary care \[[@B3-jcm-09-00783]\]. In Australia, the majority of patients with CKD stages 3--5 receive treatment from general practices \[[@B2-jcm-09-00783]\]. Prevention of CKD progression can be achieved by treatment of modifiable risk factors and avoidance of nephrotoxic medication \[[@B3-jcm-09-00783]\]. Kidney Health Australia's 'CKD management in general practice' guideline recommends, depending on the stage of CKD, adequate treatment of hypertension, dyslipidaemia, and albuminuria \[[@B3-jcm-09-00783]\]. It recommends controlling blood pressure at ≤140/90 mm Hg in patients with CKD alone and ≤130/80 mm Hg in those comorbid with albuminuria or diabetes \[[@B3-jcm-09-00783]\].

Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are first-line antihypertensive agents in CKD patients with albuminuria or diabetes \[[@B3-jcm-09-00783]\]. These classes of drugs not only lower blood pressure but also decrease the progression of albuminuria \[[@B3-jcm-09-00783]\]. Statin therapy is recommended in patients with CKD and aged 50 years or older as it reduces cardiovascular risk and progression of CKD \[[@B5-jcm-09-00783],[@B6-jcm-09-00783]\]. Australian guidelines also recommend avoiding the use of medications that can potentially damage kidney function or readily accumulate and cause toxicity \[[@B6-jcm-09-00783]\]. These medications include non-steroidal anti-inflammatory drugs (NSAID), metformin, and a high dose of digoxin \[[@B3-jcm-09-00783]\].

There is limited research investigating the quality of CKD care in Australian patients \[[@B7-jcm-09-00783],[@B8-jcm-09-00783],[@B9-jcm-09-00783],[@B10-jcm-09-00783]\]. The available studies have focused on specific classes of medications \[[@B8-jcm-09-00783],[@B9-jcm-09-00783]\] and specific regions \[[@B7-jcm-09-00783],[@B9-jcm-09-00783]\] or single centres \[[@B10-jcm-09-00783]\] that may not be generalisable to the broader CKD population in Australia. There remains a need to assess prescribing quality with validated indicators in patients with CKD. Smits et al. developed a set of 16 prescribing quality indicators (PQIs) \[[@B11-jcm-09-00783]\], which were developed according to international guidelines recommendations and are relevant to evaluate the quality of CKD care in a primary care setting \[[@B12-jcm-09-00783],[@B13-jcm-09-00783]\]. We aimed to evaluate the quality of Australian prescribing with these indicators in patients with CKD using a large and nationally representative general practice dataset.

2. Methods {#sec2-jcm-09-00783}
==========

We analysed retrospective data obtained from the NPS MedicineWise MedicineInsight dataset. The data were de-identified and extracted from the electronic health records (EHRs) of general practices and included demographics, encounters, diagnoses, prescriptions, observations, and pathology tests. NPS MedicineWise MedicineInsight is the largest geographically representative primary care dataset in Australia. As of October 2018, NPS MedicineWise MedicineInsight had recruited 671 general practices across Australia. A total of 2,974,031 included patients had at least three clinical encounters in the previous two years. Details about this dataset can be found elsewhere \[[@B2-jcm-09-00783],[@B14-jcm-09-00783],[@B15-jcm-09-00783],[@B16-jcm-09-00783]\]. We used MedicineInsight data collected from 329 general practices between 1 January 2013 and 1 June 2016.

In this study, we included patients with evidence of CKD based on having two renal function tests that were performed at least three months apart with: (1) estimated glomerular filtration rate (eGFR) values \<60 mL/min/1.73 m^2^ or (2) albumin-to-creatinine ratio (ACR) values ≥3.5 mg/mmol for females or ≥2.5 mg/mmol for males. The renal function tests were performed between 1 January 2013 and 1 June 2015. The CKD epidemiology collaboration equation (CKD-EPI) was used to calculate eGFR \[[@B17-jcm-09-00783]\]. This definition of CKD is congruent with that recommended for the diagnosis of CKD in Australian general practice \[[@B3-jcm-09-00783]\]. Regular patients (defined by the Royal Australian College of General Practitioners as those with three or more encounters in the previous two years) \[[@B16-jcm-09-00783]\] were included, if at the time of data extraction (July 2016) they were aged at least 18 years. Patients were excluded if they did not have at least one follow-up general practitioner (GP) visit between 2 June 2015 and 1 June 2016, in addition to patients who died during that period.

Variables such as age, gender, socio-economic status (based on the Index of Relative Socio-economic Advantage and Disadvantage, one of the socio-economic indexes for areas (SEIFA)) \[[@B18-jcm-09-00783]\], rurality, continuity of care (CoC), documentation of a diagnosis of CKD, and serum electrolyte levels (e.g., calcium, and phosphate) were examined. SEIFA quintile was an index developed by the Australian Bureau of Statistics (ABS) and ranks areas in Australia from 1 (most disadvantaged area) to 5 (most advantaged area) \[[@B18-jcm-09-00783]\]. Rurality was assigned according to the postcode of the patient's residence and classified as major cities, regional, remote, and very remote Australia \[[@B19-jcm-09-00783]\]. SEIFA quintile was categorised into SEIFA ≤ 3 vs. SEIFA \> 3 and rurality to major cities vs. regional and remote Australia. CoC was calculated for each included patient after the time of laboratory evidence of CKD, over the remainder of the data collection period, using the Herfindahl--Hirschman Index, which has been shown to be highly correlated with other common measures of CoC \[[@B20-jcm-09-00783]\]. Its value ranged from 0 to 1 and cut off points for low and high CoC were \<0.75 and \>=0.75, respectively. Low CoC in general practice, measured with this index, has also been associated with a higher risk of mortality \[[@B21-jcm-09-00783],[@B22-jcm-09-00783]\].

Documentation of a diagnosis of CKD was extracted from condition codes. Baseline comorbidities, including myocardial infarction, hypertension, and diabetes were examined. The comorbidities were based on 'condition flags' provided by MedicineInsight. The prescribed medications that were examined included: diuretics (anatomical therapeutic chemical (ATC) code: C03), beta-blockers (C07), calcium channel blockers (C08), ACEIs (C09A), ARBs (C09C), other agents acting on renin-angiotensin system (RAS) (C09), other antihypertensives (C02), statins (C10AA or combinations as in C10BA and C10BX), phosphate binders (A12AA04, A12AA12, V03AE, and A02AB01), erythropoiesis-stimulating agents (ESAs) (B03XA), non-steroidal anti-inflammatory drugs (NSAIDs) (M01A, M01BA and B01AC), metformin (A10BA02 or in combination as A10BD), and digoxin (C01AA05).

The recorded data included prescriptions and laboratory tests during the last four months of follow-up (between 1 February 2016 and 1 June 2016). The 16 PQIs, developed and validated by Smits et al. \[[@B11-jcm-09-00783]\] in the Netherlands, were used to evaluate this data. They were categorised into two domains: appropriate and inappropriate PQIs. Detailed definitions for all indicators are shown in Table 4. The appropriate prescribing domain includes the first nine indicators that evaluate prescribing of all antihypertensive agents in patients with hypertension, RAS inhibitors, or diuretics in patients with proteinuria or diabetes, statins, and phosphate binders. The inappropriate prescribing domain contains the remaining seven indicators that assess the prescribing of ESA in patients with CKD and haemoglobin ≥7.5 g/dL, use of NSAIDs and metformin in patients with eGFR \< 30 mL/min/1.73 m^2^, high-dose digoxin in patients with eGFR \<50 mL/min/1.73 m^2^, simultaneous use of at least two RAS inhibitors, and triple therapy with an NSAID, RAS inhibitor, and diuretic. The use of phosphate binders and ESAs was not captured in our dataset as nephrologists in Australia typically prescribe them.

Simultaneous prescribing of RAS blockers was defined as at least two of the ATC codes C09A, C09B, C09C, C09D, C09X, or combination (as in C10BX) within the last four months of the follow-up (between 1 February 2016 and 1 June 2016). Simultaneous use of NSAID, RAS blocker, and diuretic was defined as at least one prescription for each of the three classes of medications during the follow-up period. It was acknowledged that we were not capable of capturing the use of over-the-counter NSAIDs. We could also not capture whether NSAIDs were prescribed as a regular medication or for 'as needed' use.

2.1. Statistical Analysis {#sec2dot1-jcm-09-00783}
-------------------------

Patient demographics and clinical characteristics were compared between patients with and without diabetes and are presented as numbers and proportions. The proportion of patients who met PQIs criteria are shown as percentages with 95% confidence intervals (CIs). We stratified the proportion of patients meeting each indicator by gender, age, SEIFA, rurality, CKD diagnosis documentation, and CoC. Chi-square tests were used to determine differences in the quality of prescribing with patient characteristics. All data analyses and management were conducted using the statistical and graphical computing language of R \[[@B23-jcm-09-00783]\]. A two-sided *p* value of less than 0.05 was considered to indicate statistical significance.

2.2. Ethics Approval and Consent to Participate {#sec2dot2-jcm-09-00783}
-----------------------------------------------

Ethics approval was obtained from the Tasmanian Health and Medical Human Research Ethics Committee (H0015651). De-identified data obtained from the MedicineInsight for this study did not have any patient-specific information, such as date of birth, age and postcode and individual patient consent was waived for our ethics application. Patients were informed about the programme through promotional material that was displayed with the waiting room of all participating practices. Patients choice to opt-out from the programme was respected, and robust and effective security controls safeguarded their safety.

3. Results {#sec3-jcm-09-00783}
==========

3.1. Baseline Charactersitics {#sec3dot1-jcm-09-00783}
-----------------------------

The cohort was composed of 44,259 patients with evidence of CKD. Of these, 24,165 (54.6%) were females, and 70% were aged 70 years or older. Most patients (57.8%) had eGFR values between 45 and 59 mL/min/1.73 m^2^. Only a quarter of patients with evidence of CKD had documentation of the diagnosis, and documentation was less likely with increasing age (e.g., 51.3% for patients aged 30--39 years with evidence of CKD vs. 23.9% in those aged ≥80 years; *p* \< 0.001). The sociodemographic and clinical characteristics of the study participants, including medications prescribed and monitoring performed, are shown in [Table 1](#jcm-09-00783-t001){ref-type="table"}, [Table 2](#jcm-09-00783-t002){ref-type="table"} and [Table 3](#jcm-09-00783-t003){ref-type="table"}.

A total of 13,263 patients (30%) had diabetes. Of these, 11,608 (87.5%) and 6608 (87.5%) had hypertension and a history of myocardial infarction, respectively ([Table 2](#jcm-09-00783-t002){ref-type="table"}). Of 39,716 (89.7%) patients who had a recorded blood pressure measurement, 13,338 (33.6%) had uncontrolled blood pressure (\>140/90 mm Hg). The proportion of patients with uncontrolled blood pressure was slightly higher in patients with diabetes (34.4% vs. 33.2%, *p* = 0.03) than in those without diabetes. Antihypertensive medication prescribing was significantly higher in CKD patients with diabetes compared with those without diabetes (82.1% vs. 70.6%, *p* \< 0.001). Compared with CKD patients without diabetes, CKD patients with diabetes were more likely to be prescribed an ACEI/ARB (64.1% vs. 51.5%, *p* \< 0.001). Over 60% of CKD patients with diabetes were prescribed a statin compared with less than 40% without diabetes (*p* \< 0.001) ([Table 3](#jcm-09-00783-t003){ref-type="table"}).

Only a few patients had recorded treatment with phosphate binders, ESAs, and vitamin D. Therefore, the three PQIs: seven, eight, and nine that assess appropriate prescribing of phosphate binders and the two PQIs: 11 and 12 that evaluate inappropriate prescribing of vitamin D and ESAs were not operational. These five indicators were excluded from further analyses.

3.2. Appropriate Prescribing {#sec3dot2-jcm-09-00783}
----------------------------

Among patients with CKD stages 4--5 and hypertension, 79.9% overall and 83.5% of those aged ≥65 years were prescribed antihypertensive agents. The proportion of patients with microalbuminuria (ACR 2.5--25 mg/mmol for males, 3.5--35 mg/mmol for females) and diabetes who were prescribed an ACEI/ARB or an ACEI/ARB plus a diuretic were 69.9% and 20.6%, respectively. Overall, the prescribing of ACEI/ARB in patients with macroalbuminuria (ACR \> 25 mg/mmol for males, \>35 mg/mmol for females) was 62.3%. This was significantly higher in those patients aged ≥65 years than those \< 65 years (65.4% vs. 56.1%, *p* \< 0.001) and in those without documented CKD diagnosis (64.5% vs. 60.0%, *p* = 0.046) than those documented. The proportion of patients with macroalbuminuria who were prescribed an ACEI/ARB plus a diuretic was 20.4%, overall, and was significantly higher in those aged ≥65 years (22% vs. 16.7%, *p* = 0.021) than those \<65 years ([Table 4](#jcm-09-00783-t004){ref-type="table"} and [Supplementary Figure S1](#app1-jcm-09-00783){ref-type="app"}).

We examined the prescribing of statins in CKD patients with diabetes and in those aged between 50 and 65 years, as guidelines recommend statin use in both of these groups \[[@B12-jcm-09-00783]\]. The proportion of patients who were prescribed a statin was 39.9% in patients without diabetes and 60.6% in patients with diabetes. The percentage of statin prescribing was 40.8% in patients with CKD aged between 50 and 65 years. Prescribing of statins in this age group was more common in patients with a SEIFA score ≤3 than \>3 (45.3% vs. 38.9%, *p* \< 0.001) and in patients with a documented CKD diagnosis (45.1% vs. 38.9%, *p* \< 0.001) ([Table 4](#jcm-09-00783-t004){ref-type="table"} and [Supplementary Figure S1](#app1-jcm-09-00783){ref-type="app"}).

3.3. Potentially Inappropriate Prescribing {#sec3dot3-jcm-09-00783}
------------------------------------------

The percentage of patients with potentially inappropriate prescribing of an NSAID in combination with a RAS blocker and a diuretic (triple therapy) was 2.6%, overall. It was higher in those whose CKD diagnosis was documented (3.0% vs. 2.5%, *p* = 0.002) than not documented, and in those aged ≥65 years (2.7% vs. 2.0%, *p* = 0.004) than aged \<65 years. It was slightly higher in patients with SEIFA score ≤3 than \>3 (3.2% vs. 2.4%, *p* \< 0.001) and in CKD patients living in regional and remote areas than in patients living in major cities (2.8% vs. 2.5%; *p* = 0.032) ([Table 4](#jcm-09-00783-t004){ref-type="table"} and [Supplementary Figure S2](#app1-jcm-09-00783){ref-type="app"}). Among patients with eGFR \< 30 mL/min/1.73 m^2^, the proportion prescribed an NSAID was 14.3% overall and was higher in patients aged ≥65 years (15.1 vs. 9.4%, *p* \< 0.001) than those aged \<65 years and in patients with SEIFA score ≤3 (15.9% vs. 13.6%, *p* = 0.033) than those with SEIFA score \>3.

Of those patients with CKD stages 3--5 and prescribed a RAS blocker, 7.6% were prescribed at least two RAS blockers simultaneously. This was more likely in patients with SEIFA score ≤3 than \>3 (8.3% vs. 7.3%; *p* = 0.005) and in patients living in major cities than those living in regional and remote areas (8.0% vs. 7.0%; *p* = 0.002) ([Table 4](#jcm-09-00783-t004){ref-type="table"} and [Supplementary Figure S2](#app1-jcm-09-00783){ref-type="app"}).

There were 5130 patients with diabetes who were prescribed metformin. Of 1967 patients with a diagnosis of diabetes and with an eGFR \< 30 mL/min/1.73 m^2^, 278 (14.1%) were potentially inappropriately prescribed metformin. This was slightly greater in patients living in regional and remote Australia (16.8%) than those living in major cities (12.3%; *p* = 0.005) and in patients whose CKD diagnosis was not documented (16.3% vs. 12.5%; *p* = 0.018) ([Table 4](#jcm-09-00783-t004){ref-type="table"}, [Supplementary Figure S2](#app1-jcm-09-00783){ref-type="app"}).

In patients with an eGFR \< 50 mL/min/1.73 m^2^, the proportion prescribed high-dose digoxin (0.125 mg/day) was 3.8%. This was higher in females (4.1% vs. 3.3%, *p* \< 0.001), in those aged ≥65 years (4.0% vs. 1.1%, *p* \< 0.001) than aged \<65 years, and in those living in regional and remote areas (4.2% vs. 3.5%, *p* = 0.002) than those living in major cities ([Table 4](#jcm-09-00783-t004){ref-type="table"} and [Supplementary Figure S2](#app1-jcm-09-00783){ref-type="app"}).

4. Discussion {#sec4-jcm-09-00783}
=============

This study is the most extensive to date that evaluates the quality of medication prescribing in Australian general practice patients with CKD, utilising a set of 16 validated indicators and based on diabetes status \[[@B11-jcm-09-00783]\]. Potential gaps in prescribing CKD progression protective medications and avoiding nephrotoxic drugs were identified. ACEIs/ARBs in patients with proteinuria or diabetes and statins in patients aged between 50 and 65 years were found to be under-prescribed. Potential inappropriate prescribing identified included simultaneous prescribing of at least two RAS inhibitors, prescribing of NSAIDs and metformin in patients with eGFR \<30 mL/min/1.73 m^2^, and use of high-dose digoxin in patients with an eGFR \< 50 mL/min/1.73 m^2^. With at least one indicator, inappropriate prescribing was more common in patients with SEIFA ≤ 3, aged ≥65 years, or living in regional and remote Australia. Compared with patients without diabetes, patients with diabetes generally received more comprehensive blood pressure and laboratory monitoring and pharmacotherapy.

Despite strong evidence for the efficacy of ACEI/ARB to reduce proteinuria and slow progression of CKD to ESKD, less than 70% of Australian adult patients with CKD stages 3--5 with diabetes and microalbuminuria were receiving an ACEI or ARB. The prescribing of an ACEI or ARB in patients with CKD with albuminuria was slightly lower in Australian general practice compared to that reported in other developed nations \[[@B24-jcm-09-00783],[@B25-jcm-09-00783],[@B26-jcm-09-00783],[@B27-jcm-09-00783]\]. Studies from different provinces of Canada \[[@B24-jcm-09-00783],[@B25-jcm-09-00783],[@B26-jcm-09-00783]\] investigating prescribing in CKD patients reported rates of 74% to 80% for ACEI or ARB prescribing, while a study conducted in the Netherlands found prescribing in 78% and 82% of non-diabetes and diabetes patients, respectively \[[@B11-jcm-09-00783]\]. The reason for the low rate of ACEI/ARB prescribing could be non-concordance to Australian CKD treatment guidelines, including not referring patients to nephrology care \[[@B3-jcm-09-00783]\]. The cost of ACEI/ARB probably had a limited impact on the rate of their prescription as these medications are subsidized by the Australian Pharmaceutical Benefits Scheme (PBS).

It was unexpected to find no difference or even low rates of an ACEI or ARB/an ACEI or ARB plus diuretic prescribing in patients with proteinuria and documented CKD compared to those without documented CKD. This might suggest that GPs awareness of patients' CKD status did not necessarily compel them to prescribe an ACEI/ARB. They may have other valid reasons for not prescribing, including hyperkalemia, hypotension, and acute renal injury (AKI) \[[@B28-jcm-09-00783]\]. Among CKD patients with proteinuria who were receiving multiple antihypertensive agents, only a fifth use an ACEI/ARB in combination with a diuretic (double therapy) in this study. Double and triple (ACEI/ARB plus a diuretic plus an NSAID) therapies are associated with AKI \[[@B29-jcm-09-00783]\], which might have discouraged GPs from prescribing. However, compared with those with triple therapy, the risk of developing AKI is less likely in patients with double therapy \[[@B29-jcm-09-00783]\]. Combining ACEI/ARB with a thiazide diuretic instead of a loop diuretic might reduce the risk of discontinuation of ACEI/ARB \[[@B30-jcm-09-00783]\]. The risk of inducing hypotension and the associated fall in elderly patients might outweigh the renoprotective effect gained by combining an ACEI/ARB with a diuretic, and it might have also prevented GPs from prescribing \[[@B30-jcm-09-00783],[@B31-jcm-09-00783]\].

Statins are relatively well-tolerated medications and are beneficial in lowering the risk of cardiovascular events in patients with CKD \[[@B12-jcm-09-00783],[@B32-jcm-09-00783]\]. Notwithstanding the PBS restrictions on the prescribing of statins, the current Kidney Disease: Improving Global Outcomes (KDIGO) and Kidney Health Australia's guidelines \[[@B3-jcm-09-00783],[@B12-jcm-09-00783]\] recommend statin or statin/ezetimibe treatment in adults aged 50 years and over with eGFR \< 60 mL/min/1.73 m^2^ but not treated with chronic dialysis or kidney transplantation. In this study, only 40.8% of patients aged 50 to 65 years were receiving statins. These rates were less than a 54% lipid-lowering medication prescribing rate in primary care patients with CKD reported by a prior Australian study, AusHEART \[[@B33-jcm-09-00783]\]. A study by Smits et al. \[[@B11-jcm-09-00783]\] in the Netherlands using the same indicators reported a higher (74%) rate of statin prescribing in patients with CKD stages 3--5 aged 50 to 65 years. The significantly low rate of statin prescribing in those patients without documented CKD diagnosis (38.9%) suggests that lack of CKD recognition by GPs might be one reason for the low rate of statin prescribing.

Statin side effects and interactions were the main concerns of Australian patients taking statin \[[@B34-jcm-09-00783]\], and which were also cited as the most commons reasons for statin discontinuation elsewhere \[[@B35-jcm-09-00783]\]. The low rate of statin therapy in this study could be related to public concern over perceived adverse reactions following an extensive media campaign about the negative effect of statins \[[@B36-jcm-09-00783]\]. The other likely reason is the lack of PBS subsidisation for statin therapy for CKD in the absence of other indications \[[@B37-jcm-09-00783]\].

Our study indicated that patients living in relatively disadvantaged socio-economic areas (SEIFA score ≤ 3) were more likely to be prescribed potentially inappropriate NSAIDs, simultaneous use of at least two RAS inhibitors, and triple therapy (combined use of an NSAID, a RAS inhibitor and a diuretic). Similarly, patients from regional or remote areas of Australia were more likely to be prescribed potentially inappropriate digoxin, metformin, and triple therapy. These findings suggest that patients living in disadvantaged socio-economic areas, as well as regional and remote areas, may receive a lower quality of CKD care than patients living in socio-economic most advantaged areas or major cities. The health care inequality between regional/remote areas and major cities of Australia has been the subject of many reports and initiatives \[[@B38-jcm-09-00783]\]. Three in five people in remote/very remote areas did not see a specialist because of distance, and people in outer regional and remote/very remote areas were less likely to have a usual GP \[[@B38-jcm-09-00783]\]. Inequality in prescribing has also been found elsewhere. A study in France \[[@B39-jcm-09-00783]\] reported that inappropriate prescribing was highest in older people living in municipalities with low socio-economic status. A similar study conducted in Ireland \[[@B40-jcm-09-00783]\] also found that inappropriate prescribing was more prevalent in relatively deprived patients aged over 70 years.

In this study, patients with CKD and aged 65 years or over were more likely to be prescribed nephrotoxic medications: triple therapy, high-dose digoxin, and NSAIDs. One possible explanation is that some GPs may not consider an eGFR measurement between 45--59 mL/min/1.73 m^2^ as evidence of CKD in older individuals. They might consider these eGFR values as reflecting the normal physiological changes related to aging.

Unlike a previous study by Khanam et al. \[[@B31-jcm-09-00783]\], using MedicineInsight data, which found higher CoC led to better blood pressure control, this study found no significant differences in prescribing quality between patients with higher and lower CoC.

5. Strengths and Limitations {#sec5-jcm-09-00783}
============================

This study had a large sample size, and patient characteristics within the MedicineInsight dataset are similar to the Australian population \[[@B2-jcm-09-00783],[@B14-jcm-09-00783],[@B16-jcm-09-00783]\]. However, there are several limitations. Medications prescribed solely by specialists, such as nephrologists and cardiologists, who worked in hospitals and speciality clinics were not recorded in NPS MedicineWise MedicineInsight. For instance, phosphate binders and ESAs are not usually prescribed by GPs (generally prescribed by nephrologists), and thus our data were not complete on the use of these medications.

We did not account for medication contraindications and adverse drug reactions that may have prevented GPs from prescribing a specific class of medication to patients. Adverse drug reactions are recorded in free text in 'Allergies/Reactions Table' in the NPS MedicineWise MedicineInsight dataset. This table is not an event-based table and does not necessarily record each occurrence of adverse drug reaction. Free-text search for an adverse drug reaction from this table is of poor quality.

NSAIDs are also available without a prescription, but we could only obtain data on prescribed NSAIDs. Simultaneous prescribing of at least two RAS blockers within the four months might not necessarily indicate concomitant inappropriate use. It might be an overlapping period of switching from one RAS blocker monotherapy to the other. We also did not investigate the impact of medication use on patient outcomes.

GPs collected the data for clinical decision making, not for research purposes. The EHRs may not contain all sociodemographic and clinical characteristics. For instance, indigenous status was not recorded for 24.3% of the patients. There is a possibility that aspects of patients' medical history, prescriptions, and laboratory tests were recorded in notes and not included in the research data, which used specified fields and not the body of free-text consultation notes.

We noted that including only regular patients (who had three or more clinical encounters in past two years) in this study potentially introduced selection bias by including more older patients with multiple comorbidities who visited their GP more frequently. However, four in five Australian patients visited their GP multiple times in a year \[[@B41-jcm-09-00783]\], and nearly all patients could visit their GP at least three times in two years. In conclusion, we identified the potential for possible improvement in the prescribing of recommended preventive medications and deprescribing of nephrotoxic medication in patients with CKD in Australian primary care. Programmes to optimise the quality use of medications should focus on improving the prescribing practices for protective medications, such as an ACEI or ARB and a statin, and deprescribing concurrent NSAIDs and RAS blockers in patients with CKD.

The authors would like to acknowledge the NPS MedicineWise MedicineInsight for providing the data.

The data we used for this study is stored only in Australia and can be obtained from MedicineInsight. The following are available online at <https://www.mdpi.com/2077-0383/9/3/783/s1>, Figure S1: Appropriate prescribing in patients with chronic kidney disease (CKD) stages 3-5 assessed with prescribing quality indicators (PQIs), Figure S2: Potential inappropriate prescribing assessed with five prescribing quality indicators (PQIs).
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ACR

albumin-to-creatinine ratio

AKI

acute kidney injury

ARBs

angiotensin receptor blockers

ATC

anatomical therapeutic chemical

CKD

chronic kidney disease

CoC

continuity of care

EHRs

electronic health records

eGFR

estimated glomerular filtration rate

ESAs

erythropoiesis-stimulating agents

GPs

general practitioners

KDIGO

Kidney Disease: Improving Global Outcomes

NSAIDs

non-steroidal anti-inflammatory drugs

PQIs

prescribing quality indicators

RAS

renin-angiotensin system

SEIFA

socio-economic indexes for areas

jcm-09-00783-t001_Table 1

###### 

Baseline sociodemographic characteristics of patients with chronic kidney disease (CKD) overall and by diabetes status.

                                  Overall, n = 44,259 n (%)   Diabetes        *p* Value       
  ------------------------------- --------------------------- --------------- --------------- ---------
  Age groups (years)                                                                          \<0.836
  \<65                            4373 (9.9)                  3069 (9.9)      1304 (9.8)      
  ≥65                             39,886 (90.1)               27,927 (90.1)   11,959 (90.2)   
  Female                          24,165 (54.6)               17,620 (56.8)   6545 (49.3)     \<0.001
  Indigenous Status                                                                           \<0.001
  Indigenous                      436 (1.0)                   212 (0.7)       224 (1.7)       
  Non-Indigenous                  33,067 (74.7)               23,020 (74.3)   10,047 (75.8)   
  Missing                         10,756 (24.3)               7764 (25.0)     2992 (22.6)     
  SEIFA quintile \*                                                                           
  ≤3                              12,254 (27.8)               8302 (26.9)     3952 (30.0)     \<0.001
  \>3                             31,754 (72.2)               22,559 (73.1)   9225 (70.0)     
  Missing                         251 (0.6)                   165 (0.5)       86 (0.6)        
  Rurality \*                                                                                 \<0.001
  Major Cities of Australia       26,617 (60.4)               18,468 (59.9)   8149 (61.8)     
  Regional and Remote Australia   17,420 (39.6)               12,385 (40.1)   5035 (38.2)     
  Missing                         222 (0.5)                   143 (0.5)       79 (0.6)        
  GP Continuity of Care                                                                       \<0.001
  Low (\<0.75)                    17,421 (39.4)               11,917 (38.5)   5504 (41.5)     
  High (≥0.75)                    26,833 (60.6)               19,075 (61.5)   7758 (58.5)     
  Missing                         5 (0.0)                     1 (0.0)         4 (0.0)         
  Documentation of CKD            11,618 (26.3)               7722 (24.9)     3896 (29.4)     \<0.001

SEIFA, socio-economic indexes for areas; GP, general practitioner. \* Excludes patients without a recorded postcode in the electronic health record.

jcm-09-00783-t002_Table 2

###### 

Comorbidities of patients with CKD overall and by diabetes status.

  ----------------------------------------------------------------------------------------------------------
                                       Overall, n = 44,259 n (%)   Diabetes        *p* Value       
  ------------------------------------ --------------------------- --------------- --------------- ---------
  CKD Stage                                                                                        \<0.001

  Stage 3a (45--59 mL/min/1.73 m^2^)   25,562 (57.8)               18,724 (60.4)   6838 (51.6)     

  Stage 3b (30--44 mL/min/1.73 m^2^)   13,551 (30.6)               9093 (29.3)     4458 (33.6)     

  Stage 4 (15--29 mL/min/1.73 m^2^)    4186 (9.5)                  2573 (8.3)      1613 (12.2)     

  Stage 5 (\<15 mL/min/1.73 m^2^)      960 (2.2)                   606 (2.0)       354 (2.7)       

  ACR (mg/mmol)                                                                                    0.023

  Normal\                              7877 (17.8)                 3838 (12.4)     4039 (30.5)     
  \<2.5 (male)\                                                                                    
  \<3.5 (female)                                                                                   

  Microalbuminuria\                    4707 (10.6)                 1719 (5.6)      2978 (22.5)     
  2.5--25 (male)\                                                                                  
  3.5--35 (female)                                                                                 

  Macroalbuminuria\                    2427 (5.5)                  897 (2.9)       1530 (11.5)     
  \>25 (male)\                                                                                     
  \>35 (female)                                                                                    

  Missing                              29,248 (66.1)               24,532 (79.1)   4716 (35.6)     

  Indigenous Status                                                                                \<0.001

  Indigenous                           436 (1.0)                   212 (0.7)       224 (1.7)       

  Non-Indigenous                       33,067 (74.7)               23,020 (74.3)   10,047 (75.8)   

  Missing                              10,756 (24.3)               7764 (25.0)     2992 (22.6)     

  Comorbidities                                                                                    

  Hypertension                         35,386 (80.0)               23,778 (76.7)   11,608 (87.5)   \<0.001

  Myocardial infarction                17,945 (40.5)               11,688 (37.7)   6257 (47.2)     \<0.001

  Atrial fibrillation                  7038 (15.9)                 4893 (15.8)     2145 (16.2)     0.315

  Anxiety                              5658 (12.8)                 4124 (13.3)     1534 (11.6)     \<0.001

  Bipolar disorder                     505 (1.1)                   365 (1.2)       140 (1.1)       0.290

  Schizophrenia                        363 (0.8)                   227 (0.7)       136 (1.0)       0.002
  ----------------------------------------------------------------------------------------------------------

ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease.

jcm-09-00783-t003_Table 3

###### 

Proportion of patients with CKD receiving monitoring and medications by diabetes status.

                                             Total n = 44,259 n (%)   Diabetes        *p* Value       
  ------------------------------------------ ------------------------ --------------- --------------- ---------
  Blood Pressure                                                                                      
  Patients with BP Recorded                  39,716 (89.7)            27,411 (88.4)   12,305 (92.8)   \<0.001
  Low Diastolic BP (\<70 mmHg)               13,602 (34.2)            8935 (32.6)     4667 (37.9)     \<0.001
  High Systolic BP (\>140 mmHg)              13,338 (33.6)            9108 (33.2)     4230 (34.4)     0.033
  Pathology                                                                                           
  Patients with phosphate test recorded      23,133 (52.3)            16,060 (51.8)   7073 (53.3)     0.004
  Elevated phosphate level (\>1.49 mmol/L)   1322 (5.7)               872 (5.4)       450 (6.4)       0.005
  Patients with calcium test recorded        22,818 (51.6)            16,096 (51.9)   6722 (50.7)     0.017
  Elevated calcium level (\>2.54 mmol/L)     1343 (5.9)               893 (5.5)       450 (6.7)       \<0.001
  Low calcium level (\<2.10 mmol/L)          589 (2.6)                409 (2.5)       180 (2.7)       0.584
  Patients with Hb test recorded             40,601 (91.7)            28,723 (92.7)   11,878 (89.6)   \<0.001
  Low Hb level (\<7.5 mmol/L)                14,125 (34.8)            9252 (32.2)     4873 (41.0)     \<0.001
  **Medication**                                                                                      
  Antihypertensives                                                                                   
  At least one antihypertensives ^≠^         32,782 (74.1)            21,893 (70.6)   10,889 (82.1)   \<0.001
  Diuretic                                   9539 (21.6)              5956 (19.2)     3583 (27.0)     \<0.001
  Beta Blocker                               10,763 (24.3)            6862 (22.1)     3901 (29.4)     \<0.001
  Calcium Channel Blocker                    9551 (21.6)              6232 (20.1)     3319 (25.0)     \<0.001
  ACEI or ARB                                24,485 (55.3)            15,978 (51.5)   8507 (64.1)     \<0.001
  Multiple ACEI or ARB                       1859 (4.2)               1066 (3.4)      793 (6.0)       \<0.001
  Statin                                     20,411 (46.1)            12,370 (39.9)   8041 (60.6)     \<0.001
  All phosphate binders                      244 (0.6)                155 (0.5)       89 (0.7)        0.031
  Non-calcium-containing phosphate binders   67 (0.2)                 41 (0.1)        26 (0.2)        0.148
  Calcium-containing phosphate binders       182 (0.4)                119 (0.4)       63 (0.5)        0.197
  Vitamin D                                  1444 (3.3)               939 (3.0)       505 (3.8)       \<0.001
  ESAs                                       42 (0.1)                 24 (0.1)        18 (0.1)        0.098
  NSAIDs                                     7426 (16.8)              4862 (15.7)     2564 (19.3)     \<0.001
  Metformin                                  5189 (11.7)              59 \* (0.2)     5130 (38.7)     \<0.001
  Digoxin                                    1516 (3.4)               976 (3.1)       540 (4.1)       \<0.001

BP, blood pressure; Hb, haemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ESAs, erythropoiesis-stimulating agents; NSAIDs, non-steroidal anti-inflammatory drugs. ^≠^ Includes all antihypertensives with anatomical therapeutic chemical (ATC) code C02, C03, C07, C08, C09, or combinations (as in C10BX). \* Patients with a prescription for metformin who did not have a recorded diagnosis of type 2 diabetes.

jcm-09-00783-t004_Table 4

###### 

Number and proportion of patients meeting prescribing quality indicators by rurality, socio-economic indexes for areas (SEIFA) and CKD documentation \[[@B4-jcm-09-00783]\].

  Quality Indicator                                                                                                                                                                                             Numerator                   Denominator   Percentage   *p* Value             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------- ------------- ------------ ----------- --------- --
  Treatment of Hypertension                                                                                                                                                                                                                                                                  
  1. Percentage of patients aged 18 to 80 years with CKD stages 4--5 and hypertension who are prescribed antihypertensives unless undesirable because of low diastolic blood pressure                           Overall \*                                1029         1288        79.9      
  Rurality                                                                                                                                                                                                      Major cities of Australia   532           672          79.2        0.565     
  Regional and Remote Australia                                                                                                                                                                                 490                         609           80.5                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          345           433          79.7        0.947     
  \>3                                                                                                                                                                                                           677                         848           79.8                               
  CoC                                                                                                                                                                                                           High                        375           459          81.7        0.228     
  Low                                                                                                                                                                                                           654                         829           78.9                               
  CKD documented                                                                                                                                                                                                No                          380           485          78.4        0.284     
  Yes                                                                                                                                                                                                           649                         803           80.8                               
  Systolic BP                                                                                                                                                                                                   \>140 mmHg                  455           573          79.4        0.541     
  ≤140 mmHg                                                                                                                                                                                                     588                         728           80.8                               
  Age                                                                                                                                                                                                           \<65 years                  318           437          72.8        \<0.001   
  ≥65 years                                                                                                                                                                                                     711                         851           83.5                               
  Sex                                                                                                                                                                                                           Female                      450           561          80.2        0.800     
  Male                                                                                                                                                                                                          579                         727           79.6                               
  2. Percentage of patients aged 18 to 80 years with CKD stages 3--5 and macroalbuminuria treated with multiple antihypertensives who are prescribed a combination of an ACEI or ARB and a diuretic             Overall \*                                298          1464        20.4      
  Rurality                                                                                                                                                                                                      Major cities of Australia   174           837          20.8        0.679     
  Regional and Remote Australia                                                                                                                                                                                 123                         618           19.9                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          94            496          19.0        0.315     
  \>3                                                                                                                                                                                                           203                         958           21.2                               
  CoC                                                                                                                                                                                                           High                        104           528          19.7        0.639     
  Low                                                                                                                                                                                                           194                         936           20.7                               
  CKD documented                                                                                                                                                                                                No                          148           751          19.7        0.527     
  Yes                                                                                                                                                                                                           150                         713           21.0                               
  Systolic BP                                                                                                                                                                                                   \>140 mmHg                  143           643          22.2        0.123     
  ≤140 mmHg                                                                                                                                                                                                     150                         792           19.0                               
  Age                                                                                                                                                                                                           \<65 years                  74            444          16.7        0.021     
  ≥65 years                                                                                                                                                                                                     224                         1020          22                                 
  Sex                                                                                                                                                                                                           Female                      102           468          21.8        0.348     
  Male                                                                                                                                                                                                          196                         996           19.7                               
  3. Percentage of patients aged 18 to 80 years with CKD stages 3--5, microalbuminuria and diabetes treated with multiple antihypertensives who are prescribed a combination of an ACEI or ARB and a diuretic   Overall \*                                337          1634        20.6      
  Rurality                                                                                                                                                                                                      Major cities of Australia   190           956          19.9        0.270     
  Regional and Remote Australia                                                                                                                                                                                 147                         664           22.1                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          110           513          21.4        0.672     
  \>3                                                                                                                                                                                                           227                         1106          20.5                               
  CoC                                                                                                                                                                                                           High                        144           641          22.5        0.140     
  Low                                                                                                                                                                                                           193                         993           19.4                               
  CKD documented                                                                                                                                                                                                No                          216           1075         20.1        0.462     
  Yes                                                                                                                                                                                                           121                         556           21.8                               
  Systolic BP                                                                                                                                                                                                   \>140 mmHg                  119           563          21.1        0.667     
  ≤140 mmHg                                                                                                                                                                                                     213                         1053          20.2                               
  Age                                                                                                                                                                                                           \<65 years                  40            228          17.5        0.215     
  ≥65 years                                                                                                                                                                                                     297                         1406          21.1                               
  Sex                                                                                                                                                                                                           Female                      149           655          22.7        0.083     
  Male                                                                                                                                                                                                          188                         979           19.2                               
  Treatment of albuminuria                                                                                                                                                                                                                                                                   
  4. Percentage of patients aged 18 to 80 years with CKD stages 3--5 and macroalbuminuria who are prescribed an ACEI or ARB                                                                                     Overall \*                                1084         1741        62.3      
  Rurality                                                                                                                                                                                                      Major cities of Australia   636           1016         62.6        0.725     
  Regional and Remote Australia                                                                                                                                                                                 441                         714           61.8                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          353           573          61.6        0.705     
  \>3                                                                                                                                                                                                           723                         1156          62.5                               
  CoC                                                                                                                                                                                                           High                        387           645          60.0        0.135     
  Low                                                                                                                                                                                                           697                         1096          63.6                               
  CKD documented                                                                                                                                                                                                No                          578           898          64.5        0.046     
  Yes                                                                                                                                                                                                           506                         845           60.0                               
  Age                                                                                                                                                                                                           \<65 years                  331           590          56.1        \<0.001   
  ≥65 years                                                                                                                                                                                                     753                         1151          65.4                               
  Sex                                                                                                                                                                                                           Female                      327           544          60.1        0.212     
  Male                                                                                                                                                                                                          757                         1197          63.2                               
  5. Percentage of patients aged 18 to 80 years with CKD stages 3--5, microalbuminuria and diabetes who are prescribed an ACEI or ARB                                                                           Overall \*                                1252         1790        69.9      
  Rurality                                                                                                                                                                                                      Major cities of Australia   738           1064         69.4        0.516     
  Regional and Remote Australia                                                                                                                                                                                 502                         709           70.8                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          393           546          72.0        0.207     
  \>3                                                                                                                                                                                                           846                         1226          69.0                               
  CoC                                                                                                                                                                                                           High                        502           705          71.2        0.348     
  Low                                                                                                                                                                                                           750                         1085          69.1                               
  CKD documented                                                                                                                                                                                                No                          841           1179         71.3        0.075     
  Yes                                                                                                                                                                                                           411                         611           67.3                               
  Age                                                                                                                                                                                                           \<65 years                  176           259          68          0.450     
  ≥65 years                                                                                                                                                                                                     1076                        1531          70.3                               
  Sex                                                                                                                                                                                                           Female                      496           711          69.8        0.891     
  Male                                                                                                                                                                                                          759                         1079          70.1                               
  Prescription of statins                                                                                                                                                                                                                                                                    
  6. Percentage of patients aged 50 to 65 years with CKD stages 3--5 who are prescribed a statin                                                                                                                Overall \*                                1508         3693        40.8      
  Rurality                                                                                                                                                                                                      Major cities of Australia   823           2023         40.7        0.898     
  Regional and Remote Australia                                                                                                                                                                                 669                         1636          40.9                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          488           1077         45.3        \<0.001   
  \>3                                                                                                                                                                                                           1004                        2581          38.9                               
  CoC                                                                                                                                                                                                           High                        542           1292         42.0        0.311     
  Low                                                                                                                                                                                                           966                         2401          40.2                               
  CKD documented                                                                                                                                                                                                No                          991           2547         38.9        \<0.001   
  Yes                                                                                                                                                                                                           517                         1146          45.1                               
  Sex                                                                                                                                                                                                           Female                      714           1814         39.4        0.073     
  Male                                                                                                                                                                                                          794                         1879          42.3                               
  Treatment of MBD                                                                                                                                                                                                                                                                           
  7. Percentage of patients aged 18 to 80 years with CKD stages 3--5 and with an elevated phosphate level who are prescribed a phosphate binder                                                                 54                          815           6.6                                
  8. Percentage of patients aged 18 to 80 years with CKD stages 3--5 treated with phosphate binders and with an elevated calcium level who are prescribed a non-calcium-containing phosphate binder             5                           7             71.4                               
  9. Percentage of patients aged 18 to 80 years with CKD stages 3--5 treated with phosphate binders and with a low calcium level who are prescribed a calcium-containing phosphate binder                       6                           12            50.0                               
  Medication safety                                                                                                                                                                                                                                                                          
  10. Percentage of patients 18 years or older with CKD stages 3--5 and a prescription of RAS blockers who are prescribed at least two RAS blockers simultaneously                                              Overall \*                                1859         24,485      7.6       
  Rurality                                                                                                                                                                                                      Major cities of Australia   1175          14,639       8.0         0.002     
  Regional and Remote Australia                                                                                                                                                                                 678                         9732          7.0                                
  SEIFA quintile                                                                                                                                                                                                ≤3                          587           7037         8.3         0.005     
  \>3                                                                                                                                                                                                           1264                        17,317        7.3                                
  CoC                                                                                                                                                                                                           High                        727           9756         7.5         0.499     
  Low                                                                                                                                                                                                           1132                        14,729        7.7                                
  CKD documented                                                                                                                                                                                                No                          1339          18,073       7.4         0.069     
  Yes                                                                                                                                                                                                           520                         6412          8.1                                
  Age                                                                                                                                                                                                           \<65 years                  182           2076         8.8         0.035     
  ≥65 years                                                                                                                                                                                                     1677                        22,409        7.5                                
  Sex                                                                                                                                                                                                           Female                      1007          13,466       7.5         0.455     
  Male                                                                                                                                                                                                          852                         11,019        7.7                                
  11. Percentage of patients 18 years or older with CKD stages 3--5 and elevated calcium levels who are prescribed active vitamin D                                                                             67                          1343          5.0                                
  12. Percentage of patients 18 years or older with CKD stages 3--5 and Hb ≥ 7.5 who are prescribed ESA                                                                                                         0                           26,476        0.0                                
  13. Percentage of patients 18 years or older with Egfr \< 30 mL/min/1.73 m^2^ who are prescribed a NSAID                                                                                                      Overall \*                                735          5146        14.3      
  Rurality                                                                                                                                                                                                      Major cities of Australia   421           3054         13.8        0.201     
  Regional and Remote Australia                                                                                                                                                                                 312                         2072          15.1                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          238           1496         15.9        0.033     
  \>3                                                                                                                                                                                                           494                         3627          13.6                               
  CoC                                                                                                                                                                                                           High                        295           2058         14.3        0.935     
  Low                                                                                                                                                                                                           440                         3087          14.3                               
  CKD documented                                                                                                                                                                                                No                          352           2367         14.9        0.266     
  Yes                                                                                                                                                                                                           383                         2779          13.8                               
  Age                                                                                                                                                                                                           \<65 years                  68            724          9.4         \<0.001   
  ≥65 years                                                                                                                                                                                                     667                         4422          15.1                               
  Sex                                                                                                                                                                                                           Female                      360           2648         13.6        0.147     
  Male                                                                                                                                                                                                          375                         2498          15.0                               
  14. Percentage of patients 18 years or older with Egfr \< 30 mL/min/1.73 m^2^ and diabetes who are prescribed metformin                                                                                       Overall ^\*^                278           1967         14.1                  
  Rurality                                                                                                                                                                                                      Major cities of Australia   149           1208         12.3        0.005     
  Regional and Remote Australia                                                                                                                                                                                 126                         749           16.8                               
  SEIFA quintile                                                                                                                                                                                                ≤3                          80            608          13.2        0.444     
  \>3                                                                                                                                                                                                           195                         1349          14.4                               
  CoC                                                                                                                                                                                                           High                        119           829          14.4        0.810     
  Low                                                                                                                                                                                                           159                         1138          14.0                               
  CKD documented                                                                                                                                                                                                No                          136           835          16.3        0.019     
  Yes                                                                                                                                                                                                           142                         1132          12.5                               
  Age                                                                                                                                                                                                           \<65 years                  32            244          13.1        0.625     
  ≥65 years                                                                                                                                                                                                     246                         1723          14.3                               
  Sex                                                                                                                                                                                                           Female                      127           957          13.3        0.285     
  Male                                                                                                                                                                                                          151                         1010          15                                 
  15. Percentage of patients 18 years or older with eGFR \< 50 mL/min/1.73 m^2^ who are prescribed digoxin \> 0.125 mg/day                                                                                      Overall \*                  995           26,434       3.8                   
  Rurality                                                                                                                                                                                                      Major cities of Australia   558           16,020       3.5         0.002     
  Regional and Remote Australia                                                                                                                                                                                 433                         10,282        4.2                                
  SEIFA quintile                                                                                                                                                                                                ≤3                          293           7394         4.0         0.295     
  \>3                                                                                                                                                                                                           697                         18,893        3.7                                
  CoC                                                                                                                                                                                                           High                        366           10,623       3.4         0.025     
  Low                                                                                                                                                                                                           629                         15,807        4.0                                
  CKD documented                                                                                                                                                                                                No                          696           17,547       4.0         0.015     
  Yes                                                                                                                                                                                                           299                         8887          3.4                                
  Age                                                                                                                                                                                                           \<65 years                  25            2252         1.1         \<0.001   
  ≥65 years                                                                                                                                                                                                     970                         24,182        4.0                                
  Sex                                                                                                                                                                                                           Female                      596           14,411       4.1         \<0.001   
  Male                                                                                                                                                                                                          399                         12,023        3.3                                
  16. Percentage of patients 18 years or older with CKD stages 3--5 and who are prescribed with a combination of NSAID, RAS blocker and diuretic                                                                Overall \*                  1160          44,259       2.6                   
  Rurality                                                                                                                                                                                                      Major cities of Australia   663           26,617       2.5         0.032     
  Regional and Remote Australia                                                                                                                                                                                 492                         17,420        2.8                                
  SEIFA quintile                                                                                                                                                                                                ≤3                          397           12,254       3.2         \<0.001   
  \>3                                                                                                                                                                                                           757                         31,758        2.4                                
  CoC                                                                                                                                                                                                           High                        452           17,421       2.6         0.777     
  Low                                                                                                                                                                                                           708                         26,833        2.6                                
  CKD documented                                                                                                                                                                                                No                          809           32,641       2.5         0.002     
  Yes                                                                                                                                                                                                           351                         11,618        3.0                                
  Age                                                                                                                                                                                                           \<65 years                  86            4373         2.0         0.004     
  ≥65 years                                                                                                                                                                                                     1074                        39,886        2.7                                
  Sex                                                                                                                                                                                                           Female                      640           24,165       2.6         0.691     
  Male                                                                                                                                                                                                          520                         20,094        2.6                                

BP, blood pressure; CKD, chronic kidney disease; MBD, mineral and bone density; CoC, continuity of care; SEIFA, socio-economic indexes for areas; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; RAS, renin-angiotensin system; eGFR, estimated glomerular filtration rate; ESAs, erythropoiesis-stimulating agents; NSAIDs, non-steroidal anti-inflammatory drugs. \* 'Patient SEIFA', 'Patient Rurality', Patient CoC', and 'CKD documented' for the indicator does not add up to 'Overall' due to missing data.
